Information Provided By: 
Fly News Breaks for September 1, 2016
MYL, AMAG
Sep 1, 2016 | 07:52 EDT
Leerink analyst Joseph Schwartz lowered his price target for AMAG Pharmaceuticals (AMAG) to $36 from $40, saying he is wary that its Makena auto-injector will garner increased attention in 2018, similar to Mylan's (MYL) EpiPen. The analyst believes AMAG Pharmaceuticals' auto-injector will receive FDA approval but it remains to be seen whether approval timing and future potential achieve the company's expectations. He reiterates an Outperform rating on the AMAG Pharmaceuticals' shares.
News For AMAG;MYL From the Last 2 Days
There are no results for your query AMAG;MYL
